Drugs / NA17.A2 (GnTV)
last change Dec 2013 re-read 2 minutes ago

NA17.A2 (GnTV)

Peptide

Developed for
cutaneous melanoma
Investigated by
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Immutep S.A.S.

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00365937 Aug 2006 → Dec 2013 cutaneous melanoma Cliniques universitaires Saint-Luc- Université Catholique de Louvain Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NA17.A2 (GnTV) NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks” NCT00365937
Modality Peptide “The eight HLA-A2 peptides” NCT00365937